Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.
Identifieur interne : 001E71 ( PubMed/Curation ); précédent : 001E70; suivant : 001E72Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.
Auteurs : J. Laubach [États-Unis] ; L. Garderet [France] ; A. Mahindra [États-Unis] ; G. Gahrton [Suède] ; J. Caers [Belgique] ; O. Sezer [Turquie] ; P. Voorhees [États-Unis] ; X. Leleu [France] ; H E Johnsen [Danemark] ; M. Streetly [Royaume-Uni] ; A. Jurczyszyn [Pologne] ; H. Ludwig [Autriche] ; U-H Mellqvist [Suède] ; W-J Chng [Singapour] ; L. Pilarski [Canada] ; H. Einsele [Allemagne] ; J. Hou [République populaire de Chine] ; I. Turesson [Suède] ; E. Zamagni [Italie] ; C S Chim [République populaire de Chine] ; A. Mazumder [États-Unis] ; J. Westin [Suède] ; J. Lu [République populaire de Chine] ; T. Reiman ; S. Kristinsson [Suède] ; D. Joshua [Australie] ; M. Roussel [France] ; P. O'Gorman [Irlande (pays)] ; E. Terpos [Grèce] ; P. Mccarthy [États-Unis] ; M. Dimopoulos [Grèce] ; P. Moreau [France] ; R Z Orlowski [États-Unis] ; J S Miguel [Espagne] ; K C Anderson [États-Unis] ; A. Palumbo [Italie] ; S. Kumar [États-Unis] ; V. Rajkumar [États-Unis] ; B. Durie [États-Unis] ; P G Richardson [États-Unis]Source :
- Leukemia [ 1476-5551 ] ; 2016.
Descripteurs français
- KwdFr :
- Antinéoplasiques (usage thérapeutique), Guides de bonnes pratiques cliniques comme sujet, Humains, Myélome multiple (), Myélome multiple (anatomopathologie), Myélome multiple (diagnostic), Myélome multiple (traitement médicamenteux), Prise en charge de la maladie, Récidive, Thérapie de rattrapage (), Transplantation de cellules souches hématopoïétiques ().
- MESH :
- anatomopathologie : Myélome multiple.
- diagnostic : Myélome multiple.
- traitement médicamenteux : Myélome multiple.
- usage thérapeutique : Antinéoplasiques.
- Guides de bonnes pratiques cliniques comme sujet, Humains, Myélome multiple, Prise en charge de la maladie, Récidive, Thérapie de rattrapage, Transplantation de cellules souches hématopoïétiques.
English descriptors
- KwdEn :
- Antineoplastic Agents (therapeutic use), Disease Management, Hematopoietic Stem Cell Transplantation (methods), Humans, Multiple Myeloma (diagnosis), Multiple Myeloma (drug therapy), Multiple Myeloma (pathology), Multiple Myeloma (therapy), Practice Guidelines as Topic, Recurrence, Salvage Therapy (methods).
- MESH :
- chemical , therapeutic use : Antineoplastic Agents.
- diagnosis : Multiple Myeloma.
- drug therapy : Multiple Myeloma.
- methods : Hematopoietic Stem Cell Transplantation, Salvage Therapy.
- pathology : Multiple Myeloma.
- therapy : Multiple Myeloma.
- Disease Management, Humans, Practice Guidelines as Topic, Recurrence.
Abstract
The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.
DOI: 10.1038/leu.2015.356
PubMed: 26710887
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001E95
Links to Exploration step
pubmed:26710887Curation
No country items
T. Reiman<affiliation><nlm:affiliation>Saint John Regional Hospital and Dalhousie University, Saint John, NB.</nlm:affiliation><wicri:noCountry code="subField">NB</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.</title><author><name sortKey="Laubach, J" sort="Laubach, J" uniqKey="Laubach J" first="J" last="Laubach">J. Laubach</name><affiliation wicri:level="1"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Garderet, L" sort="Garderet, L" uniqKey="Garderet L" first="L" last="Garderet">L. Garderet</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Saint Antoine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint Antoine, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Mahindra, A" sort="Mahindra, A" uniqKey="Mahindra A" first="A" last="Mahindra">A. Mahindra</name><affiliation wicri:level="1"><nlm:affiliation>University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of California San Francisco, San Francisco, CA</wicri:regionArea></affiliation></author><author><name sortKey="Gahrton, G" sort="Gahrton, G" uniqKey="Gahrton G" first="G" last="Gahrton">G. Gahrton</name><affiliation wicri:level="1"><nlm:affiliation>Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm</wicri:regionArea></affiliation></author><author><name sortKey="Caers, J" sort="Caers, J" uniqKey="Caers J" first="J" last="Caers">J. Caers</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, CHU Liège, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Hematology, CHU Liège</wicri:regionArea></affiliation></author><author><name sortKey="Sezer, O" sort="Sezer, O" uniqKey="Sezer O" first="O" last="Sezer">O. Sezer</name><affiliation wicri:level="1"><nlm:affiliation>Memorial Hospital, Hematology Department, Istanbul, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Memorial Hospital, Hematology Department, Istanbul</wicri:regionArea></affiliation></author><author><name sortKey="Voorhees, P" sort="Voorhees, P" uniqKey="Voorhees P" first="P" last="Voorhees">P. Voorhees</name><affiliation wicri:level="1"><nlm:affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC</wicri:regionArea></affiliation></author><author><name sortKey="Leleu, X" sort="Leleu, X" uniqKey="Leleu X" first="X" last="Leleu">X. Leleu</name><affiliation wicri:level="1"><nlm:affiliation>Maladies du sang, hôpital Huriez, CHRU, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies du sang, hôpital Huriez, CHRU, Lille</wicri:regionArea></affiliation></author><author><name sortKey="Johnsen, H E" sort="Johnsen, H E" uniqKey="Johnsen H" first="H E" last="Johnsen">H E Johnsen</name><affiliation wicri:level="1"><nlm:affiliation>Aalborg University Hospital, Aalborg, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Aalborg University Hospital, Aalborg</wicri:regionArea></affiliation></author><author><name sortKey="Streetly, M" sort="Streetly, M" uniqKey="Streetly M" first="M" last="Streetly">M. Streetly</name><affiliation wicri:level="1"><nlm:affiliation>King's College Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King's College Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Jurczyszyn, A" sort="Jurczyszyn, A" uniqKey="Jurczyszyn A" first="A" last="Jurczyszyn">A. Jurczyszyn</name><affiliation wicri:level="1"><nlm:affiliation>Jagiellonian University Medical College, Kraków, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Jagiellonian University Medical College, Kraków</wicri:regionArea></affiliation></author><author><name sortKey="Ludwig, H" sort="Ludwig, H" uniqKey="Ludwig H" first="H" last="Ludwig">H. Ludwig</name><affiliation wicri:level="1"><nlm:affiliation>Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna</wicri:regionArea></affiliation></author><author><name sortKey="Mellqvist, U H" sort="Mellqvist, U H" uniqKey="Mellqvist U" first="U-H" last="Mellqvist">U-H Mellqvist</name><affiliation wicri:level="1"><nlm:affiliation>Sahlgrenska University Hospital, Gothenburg, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Sahlgrenska University Hospital, Gothenburg</wicri:regionArea></affiliation></author><author><name sortKey="Chng, W J" sort="Chng, W J" uniqKey="Chng W" first="W-J" last="Chng">W-J Chng</name><affiliation wicri:level="4"><nlm:affiliation>Cancer Science Institute, National University of Singapore, Singapore, Republic of Singapore.</nlm:affiliation><orgName type="university">Université nationale de Singapour</orgName><country>Singapour</country></affiliation></author><author><name sortKey="Pilarski, L" sort="Pilarski, L" uniqKey="Pilarski L" first="L" last="Pilarski">L. Pilarski</name><affiliation wicri:level="1"><nlm:affiliation>University of Alberta and Cross Cancer Institute, Edmonton, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of Alberta and Cross Cancer Institute, Edmonton</wicri:regionArea></affiliation></author><author><name sortKey="Einsele, H" sort="Einsele, H" uniqKey="Einsele H" first="H" last="Einsele">H. Einsele</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg</wicri:regionArea></affiliation></author><author><name sortKey="Hou, J" sort="Hou, J" uniqKey="Hou J" first="J" last="Hou">J. Hou</name><affiliation wicri:level="1"><nlm:affiliation>The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Turesson, I" sort="Turesson, I" uniqKey="Turesson I" first="I" last="Turesson">I. Turesson</name><affiliation wicri:level="1"><nlm:affiliation>Skano University Hospital, Malmo, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Skano University Hospital, Malmo</wicri:regionArea></affiliation></author><author><name sortKey="Zamagni, E" sort="Zamagni, E" uniqKey="Zamagni E" first="E" last="Zamagni">E. Zamagni</name><affiliation wicri:level="1"><nlm:affiliation>"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna</wicri:regionArea></affiliation></author><author><name sortKey="Chim, C S" sort="Chim, C S" uniqKey="Chim C" first="C S" last="Chim">C S Chim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Queen Mary Hospital, Hong Kong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medicine, Queen Mary Hospital, Hong Kong</wicri:regionArea></affiliation></author><author><name sortKey="Mazumder, A" sort="Mazumder, A" uniqKey="Mazumder A" first="A" last="Mazumder">A. Mazumder</name><affiliation wicri:level="1"><nlm:affiliation>NYU Comprehensive Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>NYU Comprehensive Cancer Center, New York, NY</wicri:regionArea></affiliation></author><author><name sortKey="Westin, J" sort="Westin, J" uniqKey="Westin J" first="J" last="Westin">J. Westin</name><affiliation wicri:level="1"><nlm:affiliation>Sahlgrenska University Hospital, Gothenburg, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Sahlgrenska University Hospital, Gothenburg</wicri:regionArea></affiliation></author><author><name sortKey="Lu, J" sort="Lu, J" uniqKey="Lu J" first="J" last="Lu">J. Lu</name><affiliation wicri:level="1"><nlm:affiliation>Peking University People's Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Peking University People's Hospital, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Reiman, T" sort="Reiman, T" uniqKey="Reiman T" first="T" last="Reiman">T. Reiman</name><affiliation><nlm:affiliation>Saint John Regional Hospital and Dalhousie University, Saint John, NB.</nlm:affiliation><wicri:noCountry code="subField">NB</wicri:noCountry></affiliation></author><author><name sortKey="Kristinsson, S" sort="Kristinsson, S" uniqKey="Kristinsson S" first="S" last="Kristinsson">S. Kristinsson</name><affiliation wicri:level="1"><nlm:affiliation>Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm</wicri:regionArea></affiliation></author><author><name sortKey="Joshua, D" sort="Joshua, D" uniqKey="Joshua D" first="D" last="Joshua">D. Joshua</name><affiliation wicri:level="1"><nlm:affiliation>Royal Prince Alfred Hospital, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Prince Alfred Hospital, Camperdown</wicri:regionArea></affiliation></author><author><name sortKey="Roussel, M" sort="Roussel, M" uniqKey="Roussel M" first="M" last="Roussel">M. Roussel</name><affiliation wicri:level="1"><nlm:affiliation>Hématologie clinique, hôpital Purpan, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hématologie clinique, hôpital Purpan, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="O Gorman, P" sort="O Gorman, P" uniqKey="O Gorman P" first="P" last="O'Gorman">P. O'Gorman</name><affiliation wicri:level="1"><nlm:affiliation>National Institute for cellular Biotechnology, Dublin City University, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>National Institute for cellular Biotechnology, Dublin City University, Dublin</wicri:regionArea></affiliation></author><author><name sortKey="Terpos, E" sort="Terpos, E" uniqKey="Terpos E" first="E" last="Terpos">E. Terpos</name><affiliation wicri:level="1"><nlm:affiliation>National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>National and Kapodistrian University of Athens, School of Medicine, Athens</wicri:regionArea></affiliation></author><author><name sortKey="Mccarthy, P" sort="Mccarthy, P" uniqKey="Mccarthy P" first="P" last="Mccarthy">P. Mccarthy</name><affiliation wicri:level="1"><nlm:affiliation>Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY</wicri:regionArea></affiliation></author><author><name sortKey="Dimopoulos, M" sort="Dimopoulos, M" uniqKey="Dimopoulos M" first="M" last="Dimopoulos">M. Dimopoulos</name><affiliation wicri:level="1"><nlm:affiliation>National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>National and Kapodistrian University of Athens, School of Medicine, Athens</wicri:regionArea></affiliation></author><author><name sortKey="Moreau, P" sort="Moreau, P" uniqKey="Moreau P" first="P" last="Moreau">P. Moreau</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Hotel-Dieu, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Hospital Hotel-Dieu, Nantes</wicri:regionArea></affiliation></author><author><name sortKey="Orlowski, R Z" sort="Orlowski, R Z" uniqKey="Orlowski R" first="R Z" last="Orlowski">R Z Orlowski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Miguel, J S" sort="Miguel, J S" uniqKey="Miguel J" first="J S" last="Miguel">J S Miguel</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona</wicri:regionArea></affiliation></author><author><name sortKey="Anderson, K C" sort="Anderson, K C" uniqKey="Anderson K" first="K C" last="Anderson">K C Anderson</name><affiliation wicri:level="1"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Palumbo, A" sort="Palumbo, A" uniqKey="Palumbo A" first="A" last="Palumbo">A. Palumbo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino</wicri:regionArea></affiliation></author><author><name sortKey="Kumar, S" sort="Kumar, S" uniqKey="Kumar S" first="S" last="Kumar">S. Kumar</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Rajkumar, V" sort="Rajkumar, V" uniqKey="Rajkumar V" first="V" last="Rajkumar">V. Rajkumar</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Durie, B" sort="Durie, B" uniqKey="Durie B" first="B" last="Durie">B. Durie</name><affiliation wicri:level="1"><nlm:affiliation>Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA</wicri:regionArea></affiliation></author><author><name sortKey="Richardson, P G" sort="Richardson, P G" uniqKey="Richardson P" first="P G" last="Richardson">P G Richardson</name><affiliation wicri:level="1"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26710887</idno><idno type="pmid">26710887</idno><idno type="doi">10.1038/leu.2015.356</idno><idno type="wicri:Area/PubMed/Corpus">001E95</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E95</idno><idno type="wicri:Area/PubMed/Curation">001E71</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E71</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.</title><author><name sortKey="Laubach, J" sort="Laubach, J" uniqKey="Laubach J" first="J" last="Laubach">J. Laubach</name><affiliation wicri:level="1"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Garderet, L" sort="Garderet, L" uniqKey="Garderet L" first="L" last="Garderet">L. Garderet</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Saint Antoine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Saint Antoine, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Mahindra, A" sort="Mahindra, A" uniqKey="Mahindra A" first="A" last="Mahindra">A. Mahindra</name><affiliation wicri:level="1"><nlm:affiliation>University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of California San Francisco, San Francisco, CA</wicri:regionArea></affiliation></author><author><name sortKey="Gahrton, G" sort="Gahrton, G" uniqKey="Gahrton G" first="G" last="Gahrton">G. Gahrton</name><affiliation wicri:level="1"><nlm:affiliation>Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm</wicri:regionArea></affiliation></author><author><name sortKey="Caers, J" sort="Caers, J" uniqKey="Caers J" first="J" last="Caers">J. Caers</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, CHU Liège, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Hematology, CHU Liège</wicri:regionArea></affiliation></author><author><name sortKey="Sezer, O" sort="Sezer, O" uniqKey="Sezer O" first="O" last="Sezer">O. Sezer</name><affiliation wicri:level="1"><nlm:affiliation>Memorial Hospital, Hematology Department, Istanbul, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Memorial Hospital, Hematology Department, Istanbul</wicri:regionArea></affiliation></author><author><name sortKey="Voorhees, P" sort="Voorhees, P" uniqKey="Voorhees P" first="P" last="Voorhees">P. Voorhees</name><affiliation wicri:level="1"><nlm:affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC</wicri:regionArea></affiliation></author><author><name sortKey="Leleu, X" sort="Leleu, X" uniqKey="Leleu X" first="X" last="Leleu">X. Leleu</name><affiliation wicri:level="1"><nlm:affiliation>Maladies du sang, hôpital Huriez, CHRU, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Maladies du sang, hôpital Huriez, CHRU, Lille</wicri:regionArea></affiliation></author><author><name sortKey="Johnsen, H E" sort="Johnsen, H E" uniqKey="Johnsen H" first="H E" last="Johnsen">H E Johnsen</name><affiliation wicri:level="1"><nlm:affiliation>Aalborg University Hospital, Aalborg, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Aalborg University Hospital, Aalborg</wicri:regionArea></affiliation></author><author><name sortKey="Streetly, M" sort="Streetly, M" uniqKey="Streetly M" first="M" last="Streetly">M. Streetly</name><affiliation wicri:level="1"><nlm:affiliation>King's College Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King's College Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Jurczyszyn, A" sort="Jurczyszyn, A" uniqKey="Jurczyszyn A" first="A" last="Jurczyszyn">A. Jurczyszyn</name><affiliation wicri:level="1"><nlm:affiliation>Jagiellonian University Medical College, Kraków, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Jagiellonian University Medical College, Kraków</wicri:regionArea></affiliation></author><author><name sortKey="Ludwig, H" sort="Ludwig, H" uniqKey="Ludwig H" first="H" last="Ludwig">H. Ludwig</name><affiliation wicri:level="1"><nlm:affiliation>Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna</wicri:regionArea></affiliation></author><author><name sortKey="Mellqvist, U H" sort="Mellqvist, U H" uniqKey="Mellqvist U" first="U-H" last="Mellqvist">U-H Mellqvist</name><affiliation wicri:level="1"><nlm:affiliation>Sahlgrenska University Hospital, Gothenburg, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Sahlgrenska University Hospital, Gothenburg</wicri:regionArea></affiliation></author><author><name sortKey="Chng, W J" sort="Chng, W J" uniqKey="Chng W" first="W-J" last="Chng">W-J Chng</name><affiliation wicri:level="4"><nlm:affiliation>Cancer Science Institute, National University of Singapore, Singapore, Republic of Singapore.</nlm:affiliation><orgName type="university">Université nationale de Singapour</orgName><country>Singapour</country></affiliation></author><author><name sortKey="Pilarski, L" sort="Pilarski, L" uniqKey="Pilarski L" first="L" last="Pilarski">L. Pilarski</name><affiliation wicri:level="1"><nlm:affiliation>University of Alberta and Cross Cancer Institute, Edmonton, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of Alberta and Cross Cancer Institute, Edmonton</wicri:regionArea></affiliation></author><author><name sortKey="Einsele, H" sort="Einsele, H" uniqKey="Einsele H" first="H" last="Einsele">H. Einsele</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg</wicri:regionArea></affiliation></author><author><name sortKey="Hou, J" sort="Hou, J" uniqKey="Hou J" first="J" last="Hou">J. Hou</name><affiliation wicri:level="1"><nlm:affiliation>The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Turesson, I" sort="Turesson, I" uniqKey="Turesson I" first="I" last="Turesson">I. Turesson</name><affiliation wicri:level="1"><nlm:affiliation>Skano University Hospital, Malmo, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Skano University Hospital, Malmo</wicri:regionArea></affiliation></author><author><name sortKey="Zamagni, E" sort="Zamagni, E" uniqKey="Zamagni E" first="E" last="Zamagni">E. Zamagni</name><affiliation wicri:level="1"><nlm:affiliation>"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna</wicri:regionArea></affiliation></author><author><name sortKey="Chim, C S" sort="Chim, C S" uniqKey="Chim C" first="C S" last="Chim">C S Chim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Queen Mary Hospital, Hong Kong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medicine, Queen Mary Hospital, Hong Kong</wicri:regionArea></affiliation></author><author><name sortKey="Mazumder, A" sort="Mazumder, A" uniqKey="Mazumder A" first="A" last="Mazumder">A. Mazumder</name><affiliation wicri:level="1"><nlm:affiliation>NYU Comprehensive Cancer Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>NYU Comprehensive Cancer Center, New York, NY</wicri:regionArea></affiliation></author><author><name sortKey="Westin, J" sort="Westin, J" uniqKey="Westin J" first="J" last="Westin">J. Westin</name><affiliation wicri:level="1"><nlm:affiliation>Sahlgrenska University Hospital, Gothenburg, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Sahlgrenska University Hospital, Gothenburg</wicri:regionArea></affiliation></author><author><name sortKey="Lu, J" sort="Lu, J" uniqKey="Lu J" first="J" last="Lu">J. Lu</name><affiliation wicri:level="1"><nlm:affiliation>Peking University People's Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Peking University People's Hospital, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Reiman, T" sort="Reiman, T" uniqKey="Reiman T" first="T" last="Reiman">T. Reiman</name><affiliation><nlm:affiliation>Saint John Regional Hospital and Dalhousie University, Saint John, NB.</nlm:affiliation><wicri:noCountry code="subField">NB</wicri:noCountry></affiliation></author><author><name sortKey="Kristinsson, S" sort="Kristinsson, S" uniqKey="Kristinsson S" first="S" last="Kristinsson">S. Kristinsson</name><affiliation wicri:level="1"><nlm:affiliation>Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm</wicri:regionArea></affiliation></author><author><name sortKey="Joshua, D" sort="Joshua, D" uniqKey="Joshua D" first="D" last="Joshua">D. Joshua</name><affiliation wicri:level="1"><nlm:affiliation>Royal Prince Alfred Hospital, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Prince Alfred Hospital, Camperdown</wicri:regionArea></affiliation></author><author><name sortKey="Roussel, M" sort="Roussel, M" uniqKey="Roussel M" first="M" last="Roussel">M. Roussel</name><affiliation wicri:level="1"><nlm:affiliation>Hématologie clinique, hôpital Purpan, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hématologie clinique, hôpital Purpan, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="O Gorman, P" sort="O Gorman, P" uniqKey="O Gorman P" first="P" last="O'Gorman">P. O'Gorman</name><affiliation wicri:level="1"><nlm:affiliation>National Institute for cellular Biotechnology, Dublin City University, Dublin, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>National Institute for cellular Biotechnology, Dublin City University, Dublin</wicri:regionArea></affiliation></author><author><name sortKey="Terpos, E" sort="Terpos, E" uniqKey="Terpos E" first="E" last="Terpos">E. Terpos</name><affiliation wicri:level="1"><nlm:affiliation>National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>National and Kapodistrian University of Athens, School of Medicine, Athens</wicri:regionArea></affiliation></author><author><name sortKey="Mccarthy, P" sort="Mccarthy, P" uniqKey="Mccarthy P" first="P" last="Mccarthy">P. Mccarthy</name><affiliation wicri:level="1"><nlm:affiliation>Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY</wicri:regionArea></affiliation></author><author><name sortKey="Dimopoulos, M" sort="Dimopoulos, M" uniqKey="Dimopoulos M" first="M" last="Dimopoulos">M. Dimopoulos</name><affiliation wicri:level="1"><nlm:affiliation>National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>National and Kapodistrian University of Athens, School of Medicine, Athens</wicri:regionArea></affiliation></author><author><name sortKey="Moreau, P" sort="Moreau, P" uniqKey="Moreau P" first="P" last="Moreau">P. Moreau</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Hotel-Dieu, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Hospital Hotel-Dieu, Nantes</wicri:regionArea></affiliation></author><author><name sortKey="Orlowski, R Z" sort="Orlowski, R Z" uniqKey="Orlowski R" first="R Z" last="Orlowski">R Z Orlowski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Miguel, J S" sort="Miguel, J S" uniqKey="Miguel J" first="J S" last="Miguel">J S Miguel</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona</wicri:regionArea></affiliation></author><author><name sortKey="Anderson, K C" sort="Anderson, K C" uniqKey="Anderson K" first="K C" last="Anderson">K C Anderson</name><affiliation wicri:level="1"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Palumbo, A" sort="Palumbo, A" uniqKey="Palumbo A" first="A" last="Palumbo">A. Palumbo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino</wicri:regionArea></affiliation></author><author><name sortKey="Kumar, S" sort="Kumar, S" uniqKey="Kumar S" first="S" last="Kumar">S. Kumar</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Rajkumar, V" sort="Rajkumar, V" uniqKey="Rajkumar V" first="V" last="Rajkumar">V. Rajkumar</name><affiliation wicri:level="1"><nlm:affiliation>Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Durie, B" sort="Durie, B" uniqKey="Durie B" first="B" last="Durie">B. Durie</name><affiliation wicri:level="1"><nlm:affiliation>Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA</wicri:regionArea></affiliation></author><author><name sortKey="Richardson, P G" sort="Richardson, P G" uniqKey="Richardson P" first="P G" last="Richardson">P G Richardson</name><affiliation wicri:level="1"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea></affiliation></author></analytic><series><title level="j">Leukemia</title><idno type="eISSN">1476-5551</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (therapeutic use)</term><term>Disease Management</term><term>Hematopoietic Stem Cell Transplantation (methods)</term><term>Humans</term><term>Multiple Myeloma (diagnosis)</term><term>Multiple Myeloma (drug therapy)</term><term>Multiple Myeloma (pathology)</term><term>Multiple Myeloma (therapy)</term><term>Practice Guidelines as Topic</term><term>Recurrence</term><term>Salvage Therapy (methods)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (usage thérapeutique)</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Myélome multiple ()</term><term>Myélome multiple (anatomopathologie)</term><term>Myélome multiple (diagnostic)</term><term>Myélome multiple (traitement médicamenteux)</term><term>Prise en charge de la maladie</term><term>Récidive</term><term>Thérapie de rattrapage ()</term><term>Transplantation de cellules souches hématopoïétiques ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Myélome multiple</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Myélome multiple</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Hematopoietic Stem Cell Transplantation</term><term>Salvage Therapy</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Myélome multiple</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Management</term><term>Humans</term><term>Practice Guidelines as Topic</term><term>Recurrence</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Myélome multiple</term><term>Prise en charge de la maladie</term><term>Récidive</term><term>Thérapie de rattrapage</term><term>Transplantation de cellules souches hématopoïétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26710887</PMID><DateCreated><Year>2016</Year><Month>05</Month><Day>04</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5551</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Leukemia</Title><ISOAbbreviation>Leukemia</ISOAbbreviation></Journal><ArticleTitle>Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.</ArticleTitle><Pagination><MedlinePgn>1005-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2015.356</ELocationID><Abstract><AbstractText>The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laubach</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garderet</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hôpital Saint Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahindra</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gahrton</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caers</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, CHU Liège, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sezer</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Memorial Hospital, Hematology Department, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voorhees</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leleu</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Maladies du sang, hôpital Huriez, CHRU, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnsen</LastName><ForeName>H E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Streetly</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jurczyszyn</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jagiellonian University Medical College, Kraków, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellqvist</LastName><ForeName>U-H</ForeName><Initials>UH</Initials><AffiliationInfo><Affiliation>Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chng</LastName><ForeName>W-J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Cancer Science Institute, National University of Singapore, Singapore, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilarski</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Alberta and Cross Cancer Institute, Edmonton, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Einsele</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turesson</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Skano University Hospital, Malmo, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamagni</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chim</LastName><ForeName>C S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazumder</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NYU Comprehensive Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westin</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Saint John Regional Hospital and Dalhousie University, Saint John, NB.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristinsson</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Karolinska Institutet, Center for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshua</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Royal Prince Alfred Hospital, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roussel</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hématologie clinique, hôpital Purpan, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Gorman</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Institute for cellular Biotechnology, Dublin City University, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terpos</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimopoulos</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University Hospital Hotel-Dieu, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orlowski</LastName><ForeName>R Z</ForeName><Initials>RZ</Initials><AffiliationInfo><Affiliation>Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miguel</LastName><ForeName>J S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>K C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palumbo</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajkumar</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durie</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>P G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leukemia</MedlineTA><NlmUniqueID>8704895</NlmUniqueID><ISSNLinking>0887-6924</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2013 Jun;161(6):802-10</RefSource><PMID Version="1">23594335</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Apr 20;28(12):2077-84</RefSource><PMID Version="1">20308672</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Rev Hematol. 2014 Feb;7(1):97-111</RefSource><PMID Version="1">24471924</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2004 Aug 15;22(16):3269-76</RefSource><PMID Version="1">15249589</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Oct 4;120(14):2817-25</RefSource><PMID Version="1">22833546</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Aug 15;112(4):1035-8</RefSource><PMID Version="1">18502827</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hematol J. 2004;5(2):112-7</RefSource><PMID Version="1">15048060</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2013 Oct 31;122(18):3122-8</RefSource><PMID Version="1">24014245</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Jul 5;120(1):9-19</RefSource><PMID Version="1">22498745</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2003 Jul 15;21(14):2732-9</RefSource><PMID Version="1">12860952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2013 Oct 3;122(14):2331-7</RefSource><PMID Version="1">23950178</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Dec 18;376(9758):2075-85</RefSource><PMID Version="1">21146205</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Jul 10;30(20):2475-82</RefSource><PMID Version="1">22585692</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Mar 15;17(6):1264-77</RefSource><PMID Version="1">21411442</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Sep 1;25(25):3892-901</RefSource><PMID Version="1">17679727</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2007 Jan;21(1):164-8</RefSource><PMID Version="1">17096015</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Apr 15;109(8):3588-94</RefSource><PMID Version="1">17158231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 2008 Jun;41(11):953-60</RefSource><PMID Version="1">18297115</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2001 Jul 15;98(2):492-4</RefSource><PMID Version="1">11435324</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Nov 10;29(32):4243-9</RefSource><PMID Version="1">21990396</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):389-94</RefSource><PMID Version="1">24630919</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Med. 2004 Oct 1;117(7):508-15</RefSource><PMID Version="1">15464708</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 May 5;117(18):4691-5</RefSource><PMID Version="1">21292775</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2013 Jul 1;119(13):2438-46</RefSource><PMID Version="1">23576287</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2011 May;12(5):431-40</RefSource><PMID Version="1">21507715</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2008 Feb;22(2):414-23</RefSource><PMID Version="1">18094721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1991 Oct 31;325(18):1267-73</RefSource><PMID Version="1">1922221</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2003 Jul 1;102(1):69-77</RefSource><PMID Version="1">12637329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 Feb 13;123(7):985-91</RefSource><PMID Version="1">24227817</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Oct;15(11):1195-206</RefSource><PMID Version="1">25242045</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2010 May;24(5):1037-42</RefSource><PMID Version="1">20376079</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2007 May;137(3):268-9</RefSource><PMID Version="1">17408469</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Oct;14(11):1129-40</RefSource><PMID Version="1">24055414</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2002 Oct;13(10):1636-40</RefSource><PMID Version="1">12377654</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2009 Jan;144(2):169-75</RefSource><PMID Version="1">19036114</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mayo Clin Proc. 2004 Jul;79(7):875-82</RefSource><PMID Version="1">15244383</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2013 Jul;98(7):1142-6</RefSource><PMID Version="1">23645688</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Dec 1;27(34):5713-9</RefSource><PMID Version="1">19786667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2013 Mar;19(3):445-9</RefSource><PMID Version="1">23186983</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):123-30</RefSource><PMID Version="1">23291040</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2006 Mar;132(5):584-93</RefSource><PMID Version="1">16445831</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mayo Clin Proc. 2003 Jan;78(1):34-9</RefSource><PMID Version="1">12528875</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2013 Mar 14;121(11):1961-7</RefSource><PMID Version="1">23243282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2007 Jun;12(6):664-89</RefSource><PMID Version="1">17602058</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncology. 2010;79(3-4):247-54</RefSource><PMID Version="1">21372599</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2003 May 8;348(19):1875-83</RefSource><PMID Version="1">12736280</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Oct 10;26(29):4777-83</RefSource><PMID Version="1">18645194</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2013 Jul;54(7):1459-64</RefSource><PMID Version="1">23151071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2010 Jan;148(2):335-7</RefSource><PMID Version="1">20085583</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Jul 23;114(4):772-8</RefSource><PMID Version="1">19471019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 May 17;119(20):4608-13</RefSource><PMID Version="1">22451423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2010 Jan;11(1):29-37</RefSource><PMID Version="1">19853510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2008 Jun;19(6):1160-5</RefSource><PMID Version="1">18326520</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):319-24</RefSource><PMID Version="1">23040438</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2005 Sep;90(9):1287-8</RefSource><PMID Version="1">16154860</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2013 Jul;162(2):202-9</RefSource><PMID Version="1">23692564</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Hematol. 2010 May;89(5):475-82</RefSource><PMID Version="1">19921192</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Hematol. 2012 Jul;91(7):1031-7</RefSource><PMID Version="1">22286070</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1999 Nov 18;341(21):1565-71</RefSource><PMID Version="1">10564685</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Mar 15;356(11):1110-20</RefSource><PMID Version="1">17360989</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Apr 30;113(18):4137-43</RefSource><PMID Version="1">19182205</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Jun 1;30(16):1953-9</RefSource><PMID Version="1">22547589</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Nov 22;357(21):2133-42</RefSource><PMID Version="1">18032763</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Jun 14;119(24):5661-70</RefSource><PMID Version="1">22555973</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2013 Dec;27(12):2351-6</RefSource><PMID Version="1">23670297</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2013 Apr 15;19(8):2248-56</RefSource><PMID Version="1">23447001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2004 Oct;127(2):165-72</RefSource><PMID Version="1">15461622</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hematol J. 2004;5(4):312-7</RefSource><PMID Version="1">15297847</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Hematol. 2010 Oct;89(10):1019-27</RefSource><PMID Version="1">20428873</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2012 Jan;26(1):149-57</RefSource><PMID Version="1">21799510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2010 Oct;24(10):1769-78</RefSource><PMID Version="1">20739955</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2003 Nov 1;102(9):3447-54</RefSource><PMID Version="1">12855572</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2012 Apr;18(4):617-26</RefSource><PMID Version="1">21820394</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2012 Apr;53(4):632-4</RefSource><PMID Version="1">21916831</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2010 Aug;150(3):326-33</RefSource><PMID Version="1">20553268</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2005 Jun;129(6):763-70</RefSource><PMID Version="1">15953002</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2003 Jun 26;348(26):2609-17</RefSource><PMID Version="1">12826635</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Oct;14(11):1055-66</RefSource><PMID Version="1">24007748</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2012 Aug;158(4):472-80</RefSource><PMID Version="1">22640031</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 May 1;26(13):2171-7</RefSource><PMID Version="1">18362366</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2006 Jul;91(7):929-34</RefSource><PMID Version="1">16818280</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2006 Nov 15;108(10):3458-64</RefSource><PMID Version="1">16840727</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 May 29;123(22):3414-9</RefSource><PMID Version="1">24733348</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Jan 8;372(2):142-52</RefSource><PMID Version="1">25482145</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2004 Jan;45(1):113-6</RefSource><PMID Version="1">15061206</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2006 Jan;91(1):133-6</RefSource><PMID Version="1">16434383</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Pharm Des. 2013;19(4):734-44</RefSource><PMID Version="1">23016853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Dec 8;118(24):6274-83</RefSource><PMID Version="1">21911830</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Aug 28;359(9):906-17</RefSource><PMID Version="1">18753647</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2013 Aug;98(8):1264-72</RefSource><PMID Version="1">23716559</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2003 Dec 25;349(26):2495-502</RefSource><PMID Version="1">14695409</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2007 Jul 1;67(13):6383-91</RefSource><PMID Version="1">17616698</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2010 Jan;148(2):323-31</RefSource><PMID Version="1">19912215</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2010 Mar;24(3):623-8</RefSource><PMID Version="1">20072152</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2006 Jan;91(1):141-2</RefSource><PMID Version="1">16434386</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Jul 16;114(3):522-5</RefSource><PMID Version="1">19332768</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2006 Mar 1;106(5):1084-9</RefSource><PMID Version="1">16456814</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood Cancer J. 2013 Nov 22;3:e162</RefSource><PMID Version="1">24270324</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1996 Jul 11;335(2):91-7</RefSource><PMID Version="1">8649495</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2012 May;18(5):773-9</RefSource><PMID Version="1">22062804</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Nov 22;357(21):2123-32</RefSource><PMID Version="1">18032762</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma. 2008 Jun;8(3):140-5</RefSource><PMID Version="1">18650176</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2010 Aug;16(8):1122-9</RefSource><PMID Version="1">20178853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2005 Jun 16;352(24):2487-98</RefSource><PMID Version="1">15958804</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2014 Mar;28(3):525-42</RefSource><PMID Version="1">24253022</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2010 Aug 1;116(15):3621-30</RefSource><PMID Version="1">20564132</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2003 Dec 1;21(23):4444-54</RefSource><PMID Version="1">14645435</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Aug 1;29(22):3016-22</RefSource><PMID Version="1">21730266</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Oct 20;28(30):4621-9</RefSource><PMID Version="1">20823406</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2011 Jan;52(1):34-41</RefSource><PMID Version="1">21133716</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Mar 1;111(5):2516-20</RefSource><PMID Version="1">17975015</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 2008 Oct;81(4):247-52</RefSource><PMID Version="1">18637031</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 2009 Mar;43(5):417-22</RefSource><PMID Version="1">18850013</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="N">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009101" MajorTopicYN="Y">Multiple Myeloma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>09</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26710887</ArticleId><ArticleId IdType="pii">leu2015356</ArticleId><ArticleId IdType="doi">10.1038/leu.2015.356</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001E71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26710887
|texte= Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26710887" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |